Company intelligence / Profile preview

Ji Gami

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Jigami is an early-stage biotechnology company focused on developing novel therapeutic approaches for oncology and autoimmune disorders. The company leverages a proprietary platform designed to identify and modulate specific protein-protein interactions that were previously considered undruggable. By utilizing advanced computational modeling and high-throughput screening, Jigami aims to create a pipeline of high-affinity small molecules and protein-based therapies. The company is currently in the pre-clinical phase, optimizing its lead candidates for future clinical evaluation.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProtein
Industry: Biotech

Beyond the preview

Go deeper on Ji Gami.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ji Gami.

Explore the full profile